e-learning
resources
London 2016
Tuesday, 06.09.2016
Common mechanisms in lung development and fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effects of tobramycin on pulmonary fibroblast function
Suzanne Edgar (Portsmouth, United Kingdom), Suzanne Edgar, David Laight, Janis Shute
Source:
International Congress 2016 – Common mechanisms in lung development and fibrosis
Session:
Common mechanisms in lung development and fibrosis
Session type:
Thematic Poster
Number:
4036
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Suzanne Edgar (Portsmouth, United Kingdom), Suzanne Edgar, David Laight, Janis Shute. The effects of tobramycin on pulmonary fibroblast function. Eur Respir J 2016; 48: Suppl. 60, 4036
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Efficacy of functionalized-imatinib loaded gold nanoparticles on lung fibroblastoid cells from systemic sclerosis patients
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Nintedanib inhibits fibroblast activation and ameliorates pulmonary and dermal fibrosis in models of systemic sclerosis (SSc)
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Serum B cell activating factor (BAFF) as a prognostic biomarker in interstitial lung diseases associated with connective tissue diseases
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
Source: Eur Respir J 2010; 35: 496-504
Year: 2010
Lung structure and function relation in systemic sclerosis: Application of lung densitometry
Source: International Congress 2015 – A more functional view of chest pathology
Year: 2015
Chemical exposure triggering connective tissue disease with lung involvement
Source: International Congress 2015 – Occupational disease: clinical cases and series
Year: 2015
Scleroderma lung disease: A scleroderma physiologic index (SPI) derived from lung physiology and oxygen saturation
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
A role of Foxc2 gene in mice with bleomycin-induced pulmonary fibrosis
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
B cell activating factor belonging to the TNF family might be a useful biomarker in interstitial lung diseases associated with connective tissue diseases
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Etablishing rhesus model of pulmonary fibrosis (PF) for the new drug evaluation
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis?
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy},
Source: Eur Respir J 2012; 40: 641-648
Year: 2012
Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Evaluation and treatment of interstitial lung involvement in connective tissue diseases: a clinical update
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-39-1, page=27
Year: 2005
The RANKL-OPG balance in pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
"Cyclophosphamide for the treatment of inflammation driven fibrotic interstitial lung disease"
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept